PharmaShots Weekly Snapshot (February 18 – 22, 2019)

1. Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study for Steroid-Refractory Acute Graft-Versus-Host Disease (aGvHD)

Published: 22 Feb,2019 | Tags: Mallinckrodt, Reports, Results, Therakos Photopheresis, Therapy, P-III study, Steroid-Refractory Acute Graft-Versus-Host Disease, aGvHD

2. Eurofarma Signs an Exclusive Development and Commercialization Agreement with NLS-1 Pharma for its Nalazol Therapy

Published: 22 Feb,2019 | Tags: Eurofarma, Signs, Exclusive, Development, Commercialization, Agreement, NLS-1 Pharma, ADHD, Nalazol, America

3. Janssen (J&J) Signs an Exclusive WW Research Collaboration with Morphic to Develop Human Integrins Therapies

Published: 22 Feb,2019 | Tags: Janssen, Signs, Research, Development, Agreement, Morphic, Development, Human Integrins Therapeutics

4. Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure

Published: 22 Feb,2019 | Tags: Amgen, Reports, Initiation, Second, P-III, METEORIC-HF Study, Omecamtiv Mecarbil, Patients, Heart Failure, PBO

5.  AbbVie & Eisai’s Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan

Published: 22 Feb,2019 | Tags: AbbVie, Eisai, Humira, adalimumab, Receives, Approval, Hidradenitis Suppurativa, Japan

6. Merck to Acquire Immune Design for its Technologies for $300M

Published: 21 Feb,2019 | Tags: Merck, Acquire, Immune Design, Technologies, $300M, GLAAS, ZVex

7. AbbVie’s Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

Published: 21 Feb,2019 | Tags: AbbVie, Humira, adalimumab, Receives, Health Canada, Approval, Chronic Non-Infectious Anterior Uveitis, Pediatric, Patients

8. Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

Published: 21 Feb,2019 | Tags: Novo Nordisk, Signs, Non -Exclusive, Agreement, Abbott, FreeStyle Libre Mobile App

 9. Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children’s Hospital for Glioblastoma Multiforme

Published: 21 Feb,2019 | Tags: Mustang Bio, Signs, Exclusives, Worldwide, Collaboration, Nationwide Children’s Hospital, Glioblastoma Multiforme, MB-101, C134

10. Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study for 1L Advanced Hepatocellular Carcinoma (HCC)

Published: 21 Feb,2019 | Tags: Merck, Reports, Results, Keytruda, pembrolizumab, P-III, KEYNOTE-240, 1L, Advanced Hepatocellular Carcinoma, HCC

11. Pfizer and Lilly Report Result of Tanezumab in P-III A4091059 Study for Chronic Low Back Pain (CLBP)

Published: 20 Feb,2019 | Tags: Pfizer, Lilly, Report, Results, Tanezumab, P-III, A4091059, Study, Chronic Low Back Pain,

12.  Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals’ EM-100 to Treat Ocular Itching

 Published: 20 Feb,2019 | Tags: Bausch + Lomb, Licenses, US, Commercial Rights, Eton Pharmaceuticals, EM-100, Ocular Itching, Subsidary, Bausch Health

13. Alkermes Signs a Research Collaboration with Clovis Oncology to Evaluate ALKS 4230 in Combination with Rucaparib & Lucitanib

Published: 20 Feb,2019 | Tags: Alkermes, Signs, Research, Agreement, Clovis Oncology, Evaluate, ALKS 4230, Combination, Rucaparib, Lucitanib

14. Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol, N8-GP) for Patients with Haemophilia A

Published: 20 Feb,2019 | Tags: Novo Nordisk, Esperoct, turoctocog alfa pegol, N8-GP, Receives, FDA, Approval, Adults, Children, Haemophilia A

15. Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node

Published: 20 Feb,2019 | Tags: Merck, Keytruda, pembrolizumab, Receives, FDA, Approval, Adjuvant, Treatment, Patients, Melanoma, Involvement, Lymph Node

16. AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3 Study for Refractory Advanced or Metastatic Renal Cell Carcinoma (RCC)

Published: 19 Feb,2019 | Tags: AVEO Oncology, Reports, Results, FOTIVDA, tivozanib, P-III, TIVO-3, Study, Refractory, Advanced, Metastatic, Renal Cell Carcinoma, RCC

17.  Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination with Sintilimab & IBI305 in China

Published: 19 Feb,2019 | Tags: Chipscreen Biosciences, Collaborates, Evaluate, Chidamide, Innovent Biologics, Sintilimab, Anti-VEGF, IBI305, China

18. Roche’s Polatuzumab Vedotin as Combination Therapy & Entrectinib Receives FDA’s Priority Review for r/r Diffuse DLBCL & NTRK Fusion-Positive Solid Tumors

Published: 19 Feb,2019 | Tags: Roche, Polatuzumab Vedotin, Combination, Therapy, Entrectinib, Receives, FDA, Priority Review

19.  Japan Ministry of Health Approves Use of Induced Pluripotent Stem Cells (iPSCs) for Spinal Injuries

Published: 19 Feb,2019 | Tags: Japan Ministry of Health, Approves, Induced Pluripotent Stem Cells, iPSCs, Spinal Injuries, H1’2019, Keio University

20. Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carcinoma (RCC)

Published: 19 Feb,2019 | Tags: Pfizer, Reports, Results, Bavencio, avelumab, Inlyta, axitinib, P-III, JAVELIN Renal 101 trial, 1L, Advanced, Renal, Cell Carcinoma, RCC

 21. Medtronic Reports Results of PRODIGY Study in Patients with Opioid-Induced Respiratory Depression (OIRD) 

Published: 18 Feb,2019 | Tags: Finch Therapeutics, CP101, Receives, FDA, Breakthrough Therapy Designation, BT, Recurrent Clostridium difficile, C. difficile, Infection

22. Medtronic to Recall its Dual Chamber Implantable Pulse Generators (IPGs) in the US

Published: 18 Feb,2019 | Tags: Medtronic, Recall, Dual Chamber Implantable Pulse Generators, IPGs, the US, Class I recall, the US FDA

23. Bayer Exercises its Exclusive WW Option to License Vitrakvi & BAY 2731954 with Change-In-Control Clause from Loxo Oncology

Published: 18 Feb,2019 | Tags Bayer, Exercises, Exclusive, WorldWide, Option, License, Vitrakvi, larotrectinib, BAY 2731954, LOXO-195, LOXO Oncology

24.  Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC)

Published: 18 Feb,2019 | Tags Merck, Reports, Results, Keytruda, pembrolizumab, Inlyta, axitinib, P-III, KEYNOTE-426 Study, Patients, 1L, Advanced Renal Cell Carcinoma, RCC